Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED), is focused on hard-to-detect diseases. The laboratory is equipped with state-of-the-art equipment for next-generation sequencing experiments including whole exosome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies.



  • Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high complexity testing
  • Accredited by the College of American Pathologists (CAP) in Molecular Pathology







About us

Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility, and critical infectious diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and hard-to-detect diseases and their prognosis.

The Company’s proprietary tests include ARTguide™ and FertilityDX™. ARTguide™ is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX™ is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP and CLIA accredited laboratory, equipping physicians with the most robust diagnostic tools to provide personalized precision treatment for their patients.

Discover Personalized Precision Medicine